LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Aandelen Lijst・Celldex Therapeutics Inc

Celldex Therapeutics Inc

Gesloten

SectorGezondheidszorg

29.88 -2.38

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

29.37

Max

30.43

Belangrijke statistieken
By Trading Economics
Inkomsten	-10M -67M
Winstmarge	-7,753.425
Werknemers	186
EBITDA	-9.8M -73M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+66.91% upside

Dividenden
By Dow Jones
Volgende Winsten	4 mrt 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	111M 1.6B
Vorige openingsprijs	32.26
Vorige sluitingsprijs	29.88

Nieuwssentiment

By Acuity

50%

149 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

18.91 / 20.63 Steun & Weerstand

Celldex Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 feb 2026, 23:53 UTC

Populaire aandelen

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 feb 2026, 22:23 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

27 feb 2026, 17:55 UTC

Populaire aandelen

Toronto Stocks Decline, But Remain On Track for Weekly Gains

27 feb 2026, 23:46 UTC

Acquisities, Fusies, Overnames

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 feb 2026, 23:33 UTC

Acquisities, Fusies, Overnames

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 feb 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

27 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

27 feb 2026, 21:30 UTC

Winsten

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 feb 2026, 21:30 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 feb 2026, 21:20 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 feb 2026, 21:17 UTC

Winsten

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 21:10 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 feb 2026, 21:09 UTC

Acquisities, Fusies, Overnames

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 feb 2026, 21:00 UTC

Winsten

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27 feb 2026, 20:31 UTC

Acquisities, Fusies, Overnames

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27 feb 2026, 20:24 UTC

Marktinformatie

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27 feb 2026, 20:23 UTC

Marktinformatie

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27 feb 2026, 20:12 UTC

Marktinformatie

Nike Seen With Further Challenges in China -- Market Talk

27 feb 2026, 19:44 UTC

Marktinformatie

Gold Caps Historic Month -- Market Talk

27 feb 2026, 19:39 UTC

Winsten

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 feb 2026, 19:38 UTC

Winsten

Earnings Could Push the Stock Market Higher. Too Bad About Everything Else. -- Barrons.com

27 feb 2026, 18:53 UTC

Acquisities, Fusies, Overnames

Largest U.S. Pension Takes Stake in a Hot Semi Stock, Buys More Nvidia and IonQ -- Barrons.com

27 feb 2026, 18:45 UTC

Winsten

Quantum Computing Is No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

27 feb 2026, 18:45 UTC

Marktinformatie

Bitcoin Stays Vulnerable in Choppy Geopolitical Situation -- Market Talk

27 feb 2026, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

27 feb 2026, 17:07 UTC

Winsten

Pemex Cuts 4Q Loss As Operating Results Improve

27 feb 2026, 17:00 UTC

Marktinformatie

Corn Rides Oil Momentum Higher -- Market Talk

27 feb 2026, 16:31 UTC

Marktinformatie

Canadian Economy Shows Resilience -- Market Talk

27 feb 2026, 16:17 UTC

Marktinformatie

Canada Economy is Struggling But More Rate Cuts Still a Long Shot -- Market Talk

27 feb 2026, 15:49 UTC

Winsten

Quantum Computing No Longer a Speculative Bet. IonQ's Surging Stock Drives Home That Point. -- Barrons.com

Peer Vergelijking

Prijswijziging

Celldex Therapeutics Inc Prognose

Koersdoel

By TipRanks

66.91% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 51.14 USD 66.91%

Hoogste 70 USD

Laagste 24 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Celldex Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Celldex Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

18.91 / 20.63Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

149 / 352 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Celldex Therapeutics Inc

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.